

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Feng Hao has been appointed as a non-executive Director of the Company with effect from 24 November 2017.

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Mr. Feng Hao (“Mr. Feng”) has been appointed as a non-executive Director of the Company with effect from 24 November 2017.

The biographical details of Mr. Feng are set out as below:

Mr. Feng, aged 37, currently serves as a deputy general manager and the secretary to the board of directors of Sichuan Kelun Pharmaceutical Co., Ltd. (“Sichuan Kelun”). Mr. Feng has a Master’s degree; was a teacher at the School of Economics at Huazhong University of Science and Technology; an analyst at the Actuarial Division of Taiping Life Insurance Company Limited; an actuarial advisory consultant at Watson Wyatt Consultancy (Shanghai) Ltd.; a senior manager at the investment banking division of Ping An Securities Limited; and a business director at the investment banking division of Sinolink Securities Co. Ltd. Since April 2014, Mr. Feng has been a deputy general manager and the secretary to the board of directors of Sichuan Kelun.

As at the date of this announcement, approximately 20.05% of the shares in the issued share capital of the Company is beneficially owned by Sichuan Kelun.

Mr. Feng has entered into a service agreement with the Company for a term of three years and he is subject to retirement by rotation and is eligible for re-election at the upcoming general meeting of the Company in accordance with the articles of association of the Company. Mr. Feng is entitled to receive a Director’s fee of HK\$180,000 per annum which is determined with reference to his duties and responsibilities with the Company and the prevailing market situation.

Save as disclosed above, Mr. Feng (i) does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any director, senior management or substantial or controlling shareholders of the Company; and (iii) does not hold any other positions in the Company or any subsidiaries of the Company nor hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years.

Save as disclosed above, there is no information relating to Mr. Feng that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Stock Exchange”) and there is no other matter in relation to the appointment of Mr. Feng that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Company would like to take this opportunity to express its warmest welcome to Mr. Feng for joining the Board.

By Order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 24 November 2017

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.